{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:45:31Z","timestamp":1787010331327,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide. Immune checkpoint inhibitors (ICI) have improved progression and overall survival in patients progressing on sorafenib therapy. But activation of the immune system can lead to numerous immune-related adverse events. Here we present a case of hepatocellular carcinoma with abdominal pain after initiation of pembrolizumab.\n                    <jats:sup>68<\/jats:sup>\n                    Ga-FAPi PET\/CT highlighted FAPi avid soft tissue density in the paraaortic and presacral regions with diffusely increased FAPi uptake in the thyroid, suggestive of ICI-induced retroperitoneal fibrosis and thyroiditis.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006130","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:03:36Z","timestamp":1757304216000},"page":"e305-e306","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab-Induced Retroperitoneal Fibrosis Detected on 68Ga-FAPi PET\/CT"],"prefix":"10.1097","volume":"51","author":[{"given":"Neha","family":"Agrawal","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raza A.","family":"Mahdi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwant R.","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5098-5707","authenticated-orcid":false,"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Taneja","sequence":"additional","affiliation":[{"name":"Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"R1-20260401","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.2147\/CMAR.S257188","article-title":"A review about pembrolizumab in first-line treatment of advanced NSCLC: focus on KEYNOTE studies","volume":"12","author":"Qu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R3-20260401","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"key":"R4-20260401","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti\u2013CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"Am J Roentgenol"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1754-9485.13390","article-title":"18F-FDG PET\/CT features of immune-related adverse events and pitfalls following immunotherapy","volume":"66","author":"Cherk","year":"2022","journal-title":"J Med Imaging Radiat Oncol"},{"key":"R6-20260401","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur J Cancer"},{"key":"R7-20260401","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1097\/RLU.0000000000004224","article-title":"Nivolumab immunotherapy-related skin reactions detected on 18F-FDG PET\/CT in renal cell cancer","volume":"47","author":"Thayumanavan","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R8-20260401","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1097\/RLU.0000000000003806","article-title":"18F-FDG PET\/CT imaging of immune checkpoint inhibitor-related \u201cretroperitoneal panniculitis\u201d","volume":"47","author":"Minutoli","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R9-20260401","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/RLU.0000000000003306","article-title":"Pembrolizumab-induced thyroiditis and colitis-presentation and resolution on serial FDG PET\/CT","volume":"46","author":"Nawwar","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R10-20260401","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1097\/RLU.0000000000004513","article-title":"Retroperitoneal inflammation detected on FDG PET\/CT in patient on long-term immunotherapy","volume":"48","author":"Tasnim","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1007\/s00259-019-04352-1","article-title":"Retroperitoneal fibrosis in on going anti PD-1 immunotherapy detected with 18F-FDG PET\/CT","volume":"46","author":"Moreau","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20260401","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1093\/rheumatology\/keab264","article-title":"Anti-PD-1 associated retroperitoneal fibrosis","volume":"60","author":"Daoussis","year":"2021","journal-title":"Rheumatology"},{"key":"R13-20260401","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000005875","article-title":"Application of 99mTc-FAPI-46 SPECT\/CT in evaluation of idiopathic retroperitoneal fibrosis: case report of a novel promising experience","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R14-20260401","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/RLU.0000000000004793","article-title":"Serial 68Ga-FAPI PET\/CT after treatment of immunoglobulin G4-related pancreatitis and retroperitoneal fibrosis","volume":"48","author":"Cho","year":"2023","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:01:10Z","timestamp":1775077270000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006130","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"2025-04-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}